Oxaprozin (potassium)

Oxaprozin potassium is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin potassium also inhibits the activation of NF-κB. Oxaprozin potassium induces cell apoptosis. Oxaprozin potassium shows anti-inflammatory activity. Oxaprozin potassium-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties[1][2].

Product Specifications

CAS Number

[174064-08-5]

Product Name Alternative

Oxaprozinum (potassium) ; Wy21743 (potassium)

UNSPSC

12352005

Target

Akt; Apoptosis; COX; IKK; NF-κB

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; NF-κB; PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/oxaprozin-potassium.html

Solubility

10 mM in DMSO

Smiles

O=C(O[K])CCC1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)O1

Molecular Formula

C18H14KNO3

Molecular Weight

331.41

References & Citations

[1]Ottonello L, et al. Delayed apoptosis of human monocytes exposed to immune complexes is reversed byoxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157 (2) :294-306.|[2]Montecucco F, et al. Oxaprozin-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways. J Biomed Biotechnol. 2009;2009:478785.